A probiotic solution designed to reduce signs of gastrointestinal discomfort
Regularly experiencing gut discomfort can be burdensome and can seriously impact our quality of life and freedom. Gut discomforts affects one in five people at some point in life, and twice as many women as men1. With only 5% to 19% of those affected finding comfort in available products,1 we embraced the challenge and developed a clinically studied solution4,5.
A unique probiotic strain, backed by more than 20 years of research
IBme™ has been clinically shown to help ease the abdominal pain3,4, bloating3, gas4, diarrhoea4 and constipation4 that impact quality of life5. In their most recent Global Guidelines for Irritable Bowel Syndrome (IBS), the World Gastroenterology Organization acknowledged the IBme™ strain as being the most efficacious probiotic strain for specific gut discomfort11,3 .
An effective solution needed for a common problem
Twenty percent of people are affected by gastrointestinal (GI) discomfort at some point in their lives, usually arising between the ages of 20 and 301. Market research indicates a strong opportunity to meet end users’ top desires to have the energy to enjoy life, improve sleep, experience symptom relief, and to have consistency and predictability in their lives.1 Over 90% of consumers perceive these areas to be highly important, but difficult to achieve1.
As things stand, despite utilizing accessible treatments, more than 70% of individuals with GI discomfort experience frequent symptoms.1 Forty percent of people living with abdominal pain, gas, bloating, and distention in the UK have had to cancel plans last-minute,1 while 26% have stayed at home all weekend due to their physical state.1
Key benefits of IBme™
Since day one, we’ve been committed to efficacy and clinical proof of action.
IBme™ helps ease abdominal pain,3,4 bloating3, gas4, diarrhoea4, and constipation,4 all of which impact quality of life5.
Backed by more than 20 years of research
IBme™ (historically known as the 35624® strain) is backed by more than 20 years of continuous research and testing, including gold-standard clinical trials (links opposite).
These papers have been cited more than 1,000 times in scientific publications and peer-reviewed journals. Clinical evidence of the 35624® probiotic strain has been included in numerous reviews8,9,10 with its efficacy and safety confirmed by studies across multiple countries.
A list of scientific publications on the 35624® strain can be downloaded here.3,4,5
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
O'Mahony et al. 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128: 541–551.
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome
Whorwell et al. 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American journal of gastroenterology. 101:1581–1590.
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut
Groeger et al. 2013. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 4:325-39.
Recommended by doctors, trusted by consumers
Across China, Germany, and the United States, general practitioners and gastroenterologists are the most frequently contacted health care professionals for gut discomfort, and the most popular sources of information after symptom onset.1
Bifidobacterium longum 35624® is listed as improving subjects’ global assessment of distressing gut symptoms in the World Gastroenterology Organisation’s Guidelines for Probiotics and Prebiotics11.
Backed by years of end user satisfaction
Consumers experience different feelings and pain-points at each step of their journey with digestive distress. As a result, a solution’s perceived efficacy is dictated by the issues and priorities of each individual.1 This is why it is so significant that both consumers and health care professionals validate the Bifidobacterium longum 35624® strain’s efficacy.
What is the B. longum 35624® strain and how is it unique?
IBme™ contains the bacterial strain 35624®. It is of human origin and part of the genus of bacteria called Bifidobacteria that are transferred from mother to baby at birth. It arrives in the gut alive, where it binds to the human epithelial cells and has a calming effect on the gut3,4,7,12,13.
Thousands of strains were put through the testing process to understand their properties. The 35624® strain was isolated from the healthy mucosal tissue of the terminal ileum14, from within the gut of a female volunteer.
Out of all of the possible strains, number 35624® emerged as the winner, proving to be the One-in-a-trillion solution to easing indications of gut discomfort3,4,5.
How the 35624® IBme™ strain works
When ingested, IBme™ travels through the stomach and arrives in the small intestine, where it adheres to the intestinal epithelium and mucus layer3,4,7,12,13. Here, IBme™ provides a calming and strengthening coating that among other things, counters the impairment of the gut barrier function3,4,7,12,13.
Let’s create something extraordinary together
If you’re ready to take your products the next level. We are here to help. From cutting edge biotechnology to specialist formulation and marketing. Whatever your dreams are for your brand. Together we can make it happen, let's talk.
We think you might also like these products
- Novozymes OneHealth Proprietary insights 2019, 2020, 2021, 2022.
- Own insights study + “She’s got guts survey” an independent study commissioned by Alimentary Health, March 2014
- O'Mahony et al. 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128: 541–551.
- Whorwell et al. 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. The American journal of gastroenterology. 101:1581–1590.
- Sabaté et al. 2022. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 28: 732-744
- Review Team. 2016: World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome, Journal of Clinical Gastroenterology. 50:704-713.
- Groeger et al. 2013. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 4:325-39.
- Hungin AP et al. 2013. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. Aliment Pharmacol Ther. 38:864-886.
- Brenner et al. 2009. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol.104:1033-49.
- Lyseng-Williamson. 2017. Bifidobacterium infantis 35624 as a probiotic dietary supplement: a profile of its use. Drugs & Therapy Perspectives. 33:368-374.
- Konieczna et al. 2012. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes. 3:261-6.
- Schiavi et al. 2016. The Surface-Associated Exopolysaccharide of Bifidobacterium longum 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local TH17 Responses. Appl Environ Microbiol. 82:7185-7196.
- Dunne et al. 1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 76:1-4.